Impact of US Tariffs on Aurobindo Pharma and Indian Drug Makers
Thursday, 20 February 2025, 03:30
Implications of US Tariffs on Aurobindo Pharma and Drug Makers
The U.S. is India’s largest export market for pharmaceuticals, making up over 30% of the total pharma exports in FY23-24. As drug makers like Aurobindo Pharma, Dr Reddy’s, and Sun Pharma navigate this complex landscape, they must be wary of the financial hit from potential tariffs totaling $2.25 billion.
Analysis of the Current Pharmaceutical Landscape
- The impact of tariffs on price competitiveness
- Potential revenue loss for manufacturers
- Long-term implications for product availability
What the Future Holds
Companies like Zydus Lifesciences and Lupin must strategize in response to these tariff uncertainties. Pharmexcil indicates that understanding the tariff implications is crucial for maintaining market share.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.